Maqola

ADAR1 Suppresses Interferon Signaling in Gastric Cancer Cells by MicroRNA-302a-Mediated IRF9/STAT1 Regulation

Lushang JiangDepartment of Biomedical Sciences, College of Medicine, Asan Medical Center, University of Ulsan, Seoul 05505, KoreaMin Ji ParkDepartment of Biomedical Sciences, College of Medicine, Asan Medical Center, University of Ulsan, Seoul 05505, KoreaCharles J. ChoDepartment of Biomedical Sciences, College of Medicine, Asan Medical Center, University of Ulsan, Seoul 05505, KoreaKihak LeeDepartment of Biomedical Sciences, College of Medicine, Asan Medical Center, University of Ulsan, Seoul 05505, KoreaMin Kyo JungDepartment of Convergence Medicine, College of Medicine, Asan Medical Center, University of Ulsan, Seoul 05505, KoreaChan‐Gi PackDepartment of Convergence Medicine, College of Medicine, Asan Medical Center, University of Ulsan, Seoul 05505, KoreaSeung‐Jae MyungDepartment of Gastroenterology, College of Medicine, Asan Medical Center, University of Ulsan, Seoul 05505, KoreaSuhwan ChangDepartment of Biomedical Sciences, College of Medicine, Asan Medical Center, University of Ulsan, Seoul 05505, Korea

2020en

ABI

Annotatsiya

ADAR (adenosine deaminase acting on RNA) catalyzes the deamination of adenosine to generate inosine, through its binding to double-stranded RNA (dsRNA), a phenomenon known as RNA editing. One of the functions of ADAR1 is suppressing the type I interferon (IFN) response, but its mechanism in gastric cancer is not clearly understood. We analyzed changes in RNA editing and IFN signaling in ADAR1-depleted gastric cancer cells, to clarify how ADAR1 regulates IFN signaling. Interestingly, we observed a dramatic increase in the protein level of signal transducer and activator of transcription 1 (STAT1) and interferon regulatory factor 9 (IRF9) upon ADAR1 knockdown, in the absence of type I or type II IFN treatment. However, there were no changes in protein expression or localization of the mitochondrial antiviral signaling protein (MAVS) and interferon alpha and beta-receptor subunit 2 (IFNAR2), the two known mediators of IFN production. Instead, we found that miR-302a-3p binds to the untranslated region (UTR) of IRF9 and regulate its expression. The treatment of ADAR1-depleted AGS cells with an miR-302a mimic successfully restored IRF9 as well as STAT1 protein level. Hence, our results suggest that ADAR1 regulates IFN signaling in gastric cancer through the suppression of STAT1 and IRF9 via miR-302a, which is independent from the RNA editing of known IFN production pathway.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.3390/ijms21176195

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar